McLean Asset Management Corp Has $628,000 Stake in Pfizer Inc. (NYSE:PFE)

McLean Asset Management Corp increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 181.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,770 shares of the biopharmaceutical company's stock after purchasing an additional 15,972 shares during the quarter. McLean Asset Management Corp's holdings in Pfizer were worth $628,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Tallon Kerry Patrick acquired a new stake in Pfizer in the 4th quarter valued at about $509,000. Brighton Jones LLC increased its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in Pfizer in the 4th quarter valued at about $49,000. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in Pfizer by 2.3% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 158,076 shares of the biopharmaceutical company's stock valued at $4,194,000 after acquiring an additional 3,557 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Up 0.3%

PFE traded up $0.07 during trading on Wednesday, reaching $23.42. The company had a trading volume of 24,479,046 shares, compared to its average volume of 40,980,447. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The business's fifty day moving average price is $23.05 and its 200 day moving average price is $25.03. The company has a market cap of $133.15 billion, a P/E ratio of 16.61, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm posted $0.82 earnings per share. The business's revenue was down 7.8% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.34%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PFE. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.